Background: While newer antidepressants, such as venlafaxine and paroxetine, substantially decrease hot flashes, there is no published information with regards to whether a different antidepressant will be effective when one antidepressant does not adequately relieve hot flashes.
Objective: The objective of this trial was to provide pilot information with regards to whether citalopram would effectively reduce hot flashes in patients who did not receive adequate enough hot flash reduction with venlafaxine.
Design: This was a prospective pilot trial.
Measurements: Validated patient-completed hot flash diary questionnaires were utilized for measuring hot flashes.
Subjects: Thirty patients were recruited to this trial, 22 of whom were fully evaluable.
Results: Compared to a baseline week, hot flash scores were reduced by 53% 4 weeks later. The citalopram appeared to be well tolerated with many quality-of-life and potential toxicity symptoms much improved compared to the baseline week. At the end of the 4-week treatment, 19 patients (63% of patients entering the study and 86% of the patient completing the study treatment) chose to continue to use citalopram.
Conclusion: This pilot information supports the hypothesis that citalopram will reduce hot flashes in patients with inadequate hot flash relief while taking venlafaxine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/jpm.2005.8.924 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A cultural adaptation and testing on the reliability and validity of the Chinese version of the Menopause Symptom Assessment Scale.
Menopause
January 2025
From the Department of Quality Control, Yuebei People's Hospital, Shantou University Medical College, Shaoguan, China.
Objective: The aim of this study was to modify the Chinese version of the Menopause Symptom Assessment Scale (MSAS) and evaluate its validity and reliability.
Methods: An expert panel from the gynecology and nursing domain determined items that should remain or be revised, and 30 participants were selected for the pilot study. A total of 255 women who met the criteria for inclusion were enrolled in the investigation.
Prevalence and impact of vasomotor symptoms due to menopause among women in Canada: A subgroup analysis from an international cross-sectional survey of Women with Vasomotor Symptoms Associated with Menopause (WARM Study).
Menopause
January 2025
Clinique de Recherche en Santé des Femmes, Québec City, Québec, Canada.
Objective: The aim of the study was to assess the prevalence of postmenopausal vasomotor symptoms (VMS) and the impact of VMS and related treatment patterns among perimenopausal and postmenopausal Canadian women.
Methods: A subgroup analysis of data from a cross-sectional online survey of women aged 40-65 years conducted November 4, 2021, through January 17, 2022, evaluated the prevalence of moderate/severe VMS among postmenopausal Canadian women. The analysis also assessed survey responses from perimenopausal and postmenopausal Canadian women with moderate/severe VMS who completed the Menopause-Specific Quality of Life questionnaire, Work Productivity and Activity Impairment questionnaire, and the Patient-Reported Outcomes Measurement Information System Sleep Disturbances-Short Form 8b and answered questions about treatment patterns and attitudes toward treatments.
Oral administration of ethinyl estradiol and the brain-selective estrogen prodrug DHED in a female common marmoset model of menopause: Effects on cognition, thermoregulation, and sleep.
Horm Behav
December 2024
Department of Psychological and Brain Sciences, University of Massachusetts Amherst, Amherst, MA, United States of America.
Menopausal symptoms of sleep disturbances, cognitive deficits, and hot flashes are understudied, in part due to the lack of animal models in which they co-occur. Common marmosets (Callithrix jacchus) are valuable nonhuman primates for studying these symptoms, and we examined changes in cognition (reversal learning), sleep (48 h/wk of sleep recorded by telemetry), and thermoregulation (nose temperature in response to mild external warming) in middle-aged, surgically-induced menopausal marmosets studied at baseline, during 3-week phases of ethinyl estradiol (EE, 4 μg/kg/day, p.o.
View Article and Find Full Text PDFClustering Iranian women according to their menopausal severity symptoms and exploring the factors associated with severe categories, using baseline category logit model.
BMC Womens Health
December 2024
Department of Epidemiology and Biostatistics, School of Health, Mashhad University of Medical sciences, Mashhad, Iran.
Article Synopsis
- * Researchers conducted a cross-sectional study with 664 women in Mashhad, using the Menopause Severity Symptoms Inventory (MSSI-38) to group women into three clusters based on their symptom severity: mild, moderate, and severe.
- * Results indicated that women in moderate and severe symptom clusters had significant associations with higher rates of underlying diseases, lack of physical activity, and more pregnancies, with the severe cluster being most affected by factors such as insufficient income and menopause stage.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!